Defensive sectors have beaten the S&P 500 by a wide margin in recent months, even though they are priced much higher relative to earnings estimates than the index.
DEERFIELD BEACH, Fla., Nov. 18, 2026 (GLOBE NEWSWIRE) -- OTraces, Inc., a diagnostics company developing proteomic blood tests for early cancer detection, today announced that it has selected Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, to perform reference laboratory testing for its Florida Department of Health–funded clinical trial evaluating the OTraces blood-based prostate cancer diagnostic platform.
Expansion will bring clinical trial services closer to research sites and patients while supporting global studies BURLINGTON, N.C., Nov. 17, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a collaboration with Grupo Fleury, one of Brazil's leading healthcare and diagnostic groups, with extensive laboratory infrastructure, scientific expertise and a strong presence across the Brazil healthcare ecosystem, to expand clinical trial operations in the country.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Labcorp Holdings Inc. (NYSE: LH - Get Free Report) EVP Brian Caveney sold 2,000 shares of the stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $372.04, for a total value of $744,080.00. Following the completion of the transaction, the executive vice president directly owned 34,562 shares of
Fifth Third Bancorp lessened its position in Labcorp Holdings Inc. (NYSE: LH) by 12.4% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 49,116 shares of the medical research company's stock after selling 6,956 shares during the period. Fifth Third
Eurizon Capital SGR S.p.A. lowered its position in Labcorp Holdings Inc. (NYSE: LH) by 16.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 62,346 shares of the medical research company's stock after selling 12,132 shares during the
Labcorp NYSE: LH Chief Financial Officer Julia Wang said strength in the company's central laboratory business and diagnostic testing helped drive third-quarter growth, while management prepares for a potential reduction in government reimbursement rates in 2027.